Aarti Pharmalabs Limited

rs,

August 13, 2025 To, Listing/ Compliance Department BSE LTD. Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001 SCRIP CODE: 543748 Dear Sir/Madam, To, Listing/ Compliance De

20%

220+ Products 500+ Global Clients 60 6 3 Patents Filed Manufacturing Units USFDA Units 15-20% Global Market Share in Xanthine 50+ Export Countries 2,200+ Employees 3 State-of-the-art R&

0.19x

50+ Export Countries 2,200+ Employees 3 State-of-the-art R&D facilities 53 35 US DMF CEP 0.19x Net Debt/Equity AA- Credit rating Aarti Pharmalabs Limited 2 1COMPANY OVERVIEW 2 BUSINESS

INR 130

ited (APL) is part of the Aarti group – a diversified chemical conglomerate with group turnover of INR 130+ bn (FY25) • Globally recognized manufacturer of generic API, Xanthine derivatives and a leading p

19%

, and COFEPRIS (Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 15,112 15,021 19% 20% 23% 25% 3,753 • Strategically located in western India with proximity to ports FY23 FY24

23%

PRIS (Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 15,112 15,021 19% 20% 23% 25% 3,753 • Strategically located in western India with proximity to ports FY23 FY24 FY25 Q1

25%

(Mexico) STANDALONE REVENUE (INR Mn) & EBITDA MARGINS (%) 17,714 15,112 15,021 19% 20% 23% 25% 3,753 • Strategically located in western India with proximity to ports FY23 FY24 FY25 Q1-FY26

49%

ertise in novel chemistries; Largest manufacturer of Xanthine Derivatives in India Domestic, 49% International, 51% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as

51%

istries; Largest manufacturer of Xanthine Derivatives in India Domestic, 49% International, 51% Aarti Pharmalabs Limited Note: FY22 numbers are for a period of 9 months as the demerger date was

21 MW

for a period of 9 months as the demerger date was 1st Jul 2021 4 KEY MILESTONES 2024 • Started 21 MW solar power project at Akola, Maharashtra Expansion of semi-commercial production block at Vapi •

5%

t plant scale in FY25 40+ 70+3 Products developed and manufactured on kilo-lab scale in FY25 5% 70+3 R&D Spend (as a percent of API+Int & CDMO sales ) in FY25 108 3 42 Cr 70+3 R&D Proces

43.5%

Xanthine Derivatives & Allied Products API & Intermediates CDMO/CMO QUARTERLY REVENUE BREAK-UP 43.5% 43.6% 12.9% FY25 53.6% 49.6% 43.9% 2.4% Q1-FY25 40.8% 9.6% Q1-FY26 CDMO/CMO API & Inte

Valorem Advisors Disclaimer

1

Valorem Advisors Disclaimer

Valorem Advisors is an Independent Investor Relations Management Service company. This Presentation has been prepared by Valorem Advisors based on information and data which the Company considers reliable, but Valorem Advisors and the Company makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this Presentation. This Presentation may not be all inclusive and may not contain all of the information that you may consider material. Any liability in respect of the contents of, or any omission from, this Presentation is expressly excluded. Valorem Advisors also hereby certifies that the directors or employees of Valorem Advisors do not own any stock in personal or company capacity of the Company under review. For further details, please feel free to contact our Investor Relations Representatives: Mr. Anuj Sonpal Valorem Advisors Tel: +91-22-4903 9500 Email: a